CARDIOTOXICIDAD POR QUIMIOTERAPIA PDF

Published by on September 10, 2021
Categories: Marketing

Download Citation on ResearchGate | On Dec 1, , Edwin Arévalo Guerrero and others published Rol del strain miocárdico en. Abstract. RUIZ-MORI, Enrique; AYALA-BUSTAMANTE, Leonor; BURGOS- BUSTAMANTE, Jorge and PACHECO ROMAN, Cristian. Chemotherapy-induced . Resumen. RUIZ-MORI, Enrique; AYALA-BUSTAMANTE, Leonor; BURGOS- BUSTAMANTE, Jorge y PACHECO ROMAN, Cristian. Chemotherapy-induced.

Author: Dounris Faelmaran
Country: Chile
Language: English (Spanish)
Genre: Spiritual
Published (Last): 8 December 2008
Pages: 462
PDF File Size: 3.21 Mb
ePub File Size: 16.13 Mb
ISBN: 715-8-51566-283-9
Downloads: 71484
Price: Free* [*Free Regsitration Required]
Uploader: Doukinos

Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. The objective of this article is to review the state of the art of the chemotherapy-induced cardiotoxicity, as well as to synthesize the different cardiotoxic effects, cardiotoxic mechanisms and methods that have been developed for its diagnosis and prevention. The role of catalase in pulmonary fibrosis.

Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Pentostatin increases the acute toxicity of high dose cyclophosphamide.

ErbB2 is essential in the quimiotefapia of dilated cardiomyopathy. Detection of anthracycline-induced cardiotoxicity. Adverse cardio- vascular effects of vinorelbine in non-small-cell bronchial carcinoma.

A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: Cardiotoxicity is a known adverse event of oncologic therapy that many times limits a correct regimen of administration thus lowering efficacy; therefore, understanding pathophysiological and molecular bases is essential in order to determine preventive and therapeutical measures that can allow a reduction in the incidence of toxicity, without interfering in pr efficacy of the cancer therapy.

  BYRON EDDE RADAR PRINCIPLES PDF

Recentemente, o estudo experimental de Casini S. Tiribelli M, Medeot M. Clin Oncol R Coll Radiol. Quimioterpaia cancer and atrial fibrillation: Doxorubicin-induced congestive heart failure in adults. Cardiotoxicity induced by chemotherapy. How to cite this article. Tubulin polymerization modifies cardiac sodium channel expression and gating.

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. J Natl Cancer Inst. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.

[Anthracycline-induced cardiotoxicity: report of fatal cases].

Int J Immunopathol Pharmacol. Guidelines for the management of antiplatelet therapy in patients with coronary stents undergoing non-cardiac surgery.

Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. Results of the survival and ventricular enlargement trial.

Recomenda-se manter o paciente em normovolemia e utilizar com cautela anti-hipertensivos durante o tratamento com o bortezomibe. The objective of this article is to review the state of the art of the chemotherapy-induced cardiotoxicity, as well as to synthesize quimiotearpia different cardiotoxic effects, cardiotoxic mechanisms and methods that have been developed for its diagnosis and prevention Palabras clave: Mechanisms of anthracycline cardiac injury: Approaches to risk-stratifying cancer patients for venous thromboembolism.

  CATACLISMO DE DAMOCLES PDF

Cardiotoxicidad inducida por quimioterapia

Medina PJ, Goodin S. Utility of prechemotherapy echocardiographical assessment of cardiac abnormalities. Seven-year experience using serial radionuclide angiocardiography.

Local anaesthetics do not affect protein kinase C function in intact neuroblastoma cells. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease.

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: Management of hypertension in angiogenesis inhibitor-treated patients. That is why pharmacological development has emerged for improving survival and remission rates.